Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and
being developed by Gedeon Richter Plc. for weight management.
This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study
in the clinical development program for RGH-706. The aim of this study is to evaluate the
efficacy, safety, and tolerability of RGH-706 in patients with Prader-Willi Syndrome (PWS).